Ramkumar Shreya P, Lal Devyani, Miglani Amar
Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic Hospital, Phoenix, AZ, United States.
Saint Louis University School of Medicine, Saint Louis, MO, United States.
Front Allergy. 2023 Mar 10;4:1137907. doi: 10.3389/falgy.2023.1137907. eCollection 2023.
Shared decision-making is an approach where physicians and patients work together to determine a personalized treatment course. Such an approach is integral to patient-centered care in chronic rhinosinusitis with nasal polyps (CRSwNP). CRSwNP is a chronic inflammatory condition of the sinonasal cavity that can severely impact physical health, smell, and quality of life (QOL). Traditional standard-of-care treatment options include topical (i.e. sprays) and oral corticosteroids and endoscopic sinus surgery, but more recently, novel corticosteroid delivery methods (i.e. high volume irrigations, recently-approved exhalation breath-powered delivering devices, and drug-eluting steroid implants) and 3 new FDA approved biologics directed against type II immunomodulators have become available. The availability of these therapeutics offers exciting new opportunities in CRSwNP management but requires personalized and shared-decision making as each modality has variable impacts on CRSwNP and related comorbid conditions. Studies have published treatment algorithms, but the practical use of these lean guidelines is heavily influenced by the lens of the treating physician, the most common being otolaryngologists and allergy immunologists. Clinical equipoise occurs when there is no basis for one intervention to be regarded as "better" than another. While most guidelines, in general, support the use of topical corticosteroids with or without oral corticosteroids followed by ESS for the majority of unoperated CRSwNP patients, there are situations of clinical equipoise that arise particularly in CRSwNP who have failed surgery or those with severe comorbid conditions. In the shared decision-making process, clinicians and patients must consider symptomatology, goals, comfort, compliance, treatment efficacy, and treatment cost when determining the initial choice of therapy and escalation of therapy with the potential use of multiple modalities for recalcitrant CRSwNP. A summary of salient considerations that might constitute shared decision-making is presented in this summary.
共同决策是一种医生和患者共同努力确定个性化治疗方案的方法。这种方法对于以患者为中心的慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)护理至关重要。CRSwNP是鼻窦腔的一种慢性炎症性疾病,会严重影响身体健康、嗅觉和生活质量(QOL)。传统的标准治疗选择包括局部(即喷雾剂)和口服皮质类固醇以及内窥镜鼻窦手术,但最近,新型皮质类固醇给药方法(即大容量冲洗、最近批准的呼气动力给药装置和药物洗脱类固醇植入物)以及3种新的美国食品药品监督管理局(FDA)批准的针对II型免疫调节剂的生物制剂已经问世。这些治疗方法的出现为CRSwNP的管理提供了令人兴奋的新机会,但由于每种治疗方式对CRSwNP和相关合并症的影响各不相同,因此需要个性化和共同决策。已有研究发表了治疗算法,但这些精简指南的实际应用在很大程度上受到治疗医生视角的影响,最常见的是耳鼻喉科医生和过敏免疫科医生。当没有依据认为一种干预措施比另一种“更好”时,就会出现临床 equipoise。虽然大多数指南总体上支持对大多数未经手术的CRSwNP患者使用局部皮质类固醇(无论是否联合口服皮质类固醇),然后进行ESS,但在特别是手术失败的CRSwNP患者或患有严重合并症的患者中会出现临床equipoise情况。在共同决策过程中,临床医生和患者在确定初始治疗选择以及对于顽固的CRSwNP可能使用多种治疗方式进行治疗升级时,必须考虑症状、目标、舒适度、依从性、治疗效果和治疗成本。本综述介绍了可能构成共同决策的重要考虑因素总结。